In the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.5, with a high estimate of $30.00 and a low estimate of $25.00. This current average reflects an increase of 10.0% from the previous average price target of $25.00.

Deciphering Analyst Ratings: An In-Depth Analysis

The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Artivion's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Artivion analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Artivion: A Closer Look

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.

Artivion: Delving into Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Artivion's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.06% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Artivion's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.71%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.6%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Artivion's ROA excels beyond industry benchmarks, reaching 0.95%. This signifies efficient management of assets and strong financial health.

Debt Management: Artivion's debt-to-equity ratio surpasses industry norms, standing at 1.23. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.